Most Read Articles
Pearl Toh, 15 hours ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 2 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Sodium benzoate augments clozapine for schizophrenia

10 Feb 2018
The second generation injection may cost up to HK$5000 per month.

Sodium benzoate appears to augment the effects of clozapine, according to a recent study, which shows that the combination therapy results in significant improvements in symptomatology in clozapine-resistant schizophrenia patients.

The randomized, double-blind, placebo-controlled trial included 60 schizophrenia patients stabilized with clozapine who were randomized to receive one of three add-on treatments: 1 g/day of sodium benzoate (n=20), 2 g/day of sodium benzoate (n=20) or placebo (n=20). Add-on treatment was administered for an additional 60 days.

Both doses of sodium benzoate yielded significantly greater changes from baseline in the Scales for the Assessment of Negative Symptoms (SANS-20) scores relative to placebo at 6 weeks (p=0.029 for 1 g; p=0.031 for 2 g).

In comparison, only the 2-g sodium benzoate treatment resulted in significant 6-week improvements in the Positive and Negative Syndrome Scale (PANSS) scores compared with placebo (p=0.006).

Scores in the quality of life scale were also significantly better in the 2-g sodium benzoate vs placebo group at 6 weeks (p=0.009). No such effect was observed with 1 g of the add-on treatment.

In terms of secondary outcomes, neither 1 g or 2 g of add-on sodium benzoate resulted in significant 6-week improvements in depression, as per the Hamilton rating scale for depression (p=0.729 and p=0.114, respectively), and endpoint improvements in cognitive function (p=0.185 and p=0.930, respectively).

Minimal extrapyramidal syndrome was reported in all three groups both at baseline and at the conclusion of the study.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 15 hours ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 2 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.